SEC Form 4 · accession 0001209191-17-002384
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Matthew Singleton
Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 7:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.19 | Jan 3, 2017 | A | 16,000 | A | Jan 3, 2018 | Jan 3, 2027 | Common Stock | 16,000 | 16,000 | D |